Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature.

The emergence of temozolomide as an effective alkylating agent with little acute toxicity or cumulative myelosuppression has led to protracted courses of chemotherapy for many patients with gliomas. Secondary, or treatment-related, myelodysplasia (t-MDS) and acute myelogenous leukemia (t-AML) are life-threatening complications of alkylating chemotherapy and have been reported in patients with primary brain tumors. We describe a case of temozolomide-related t-MDS/AML and discuss the clinical features of this condition. Administration of an alkylating agent in patient populations with long median survivals must be undertaken with an understanding of the potential for this treatment complication.

[1]  K. Ballen.  New trends in umbilical cord blood transplantation. , 2005, Blood.

[2]  J. Pedersen‐Bjergaard.  Insights into leukemogenesis from therapy-related leukemia. , 2005, The New England journal of medicine.

[3]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[4]  M. Chiang,et al.  Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma , 2005, Journal of Neuro-Oncology.

[5]  K. Hoang-Xuan,et al.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Sonali M. Smith,et al.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.

[7]  M. Rosenblum,et al.  Therapy-related Myelodysplastic Syndrome (t-MDS) in a Patient with Anaplastic Astrocytoma: Successful Treatment with Allogeneic Bone Marrow Transplant , 2001, Journal of Neuro-Oncology.

[8]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  P. Beale,et al.  Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies , 1999, British Journal of Cancer.

[10]  J. Gockerman,et al.  Acute leukemia following treatment of malignant glioma , 1998, Journal of Neuro-Oncology.

[11]  D. Gilliland,et al.  Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia , 1997, Bone Marrow Transplantation.

[12]  H. Hansen,et al.  RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE Relation to Age, Cumulative Dose of Alkylating Agents, and Time from Chemotherapy , 1987, The Lancet.

[13]  A. Audebert,et al.  Two cases of acute leukemia following treatment of malignant glioma , 1983, Cancer.